Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI3506 Administered as Single Ascending Doses in Healthy Adult Subjects With a History of Mild Atopy and as Multiple Ascending Doses in Subjects COPD

Trial Profile

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI3506 Administered as Single Ascending Doses in Healthy Adult Subjects With a History of Mild Atopy and as Multiple Ascending Doses in Subjects COPD

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs MEDI-3506 (Primary) ; MEDI-3506 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 20 Oct 2017 Planned End Date changed from 3 Dec 2018 to 25 Jan 2019.
    • 20 Oct 2017 Planned primary completion date changed from 3 Dec 2018 to 25 Jan 2019.
    • 13 Jun 2017 Planned End Date changed from 20 Nov 2018 to 3 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top